y01G Antibody

What is the 1G01 antibody and how was it discovered?

The 1G01 antibody is a human monoclonal antibody that was isolated from a donor infected with an H3N2 influenza virus. It was discovered through single plasmablast sorting from peripheral blood mononuclear cells (PBMCs) collected on day 5 after the onset of symptomatic illness. The antibody was identified by screening 45 monoclonal antibodies for binding to recombinant H3 HA, N2 NA, nucleoprotein, and matrix protein 1. Three antibodies from this screening, including 1G01, demonstrated binding to the N2 NA of the seasonal influenza virus strain A/Hong Kong/4801/2014 (H3N2), which was presumably closely related to the strain that caused the infection .

The 1G01 antibody belongs to a three-member clonal family along with 1G04 and 1E01, where IGHV3-20 and IGKV1-9 encode the IGHV and IGLV genes, respectively. These antibodies likely originated from memory B cells as evidenced by the accumulation of many somatic hypermutations, particularly in the IGHV genes. Among the three family members, 1G01 showed the highest number of mutations with 19 amino acid differences from the germline gene IGHV3-20*04, compared to 12 and 14 differences for 1G04 and 1E01, respectively . The extensive somatic hypermutation observed in 1G01 likely contributes to its exceptionally broad binding profile across influenza subtypes.

What is the binding profile of 1G01 antibody compared to related antibodies?

The 1G01 antibody demonstrates the broadest binding activity among the three related antibodies (1G04, 1E01, and 1G01). It shows binding to all group 1 neuraminidases (N1, N4, N5, and N8), all group 2 neuraminidases (N2, N3, N6, N7, and N9), as well as neuraminidases from both influenza B virus lineages (B/Victoria/2/87 and B/Yamagata/16/88). This remarkable breadth sets 1G01 apart as an exceptionally cross-reactive anti-neuraminidase antibody .

In comparison, 1G04 shows more limited binding, primarily to N2 NAs (group 2) from seasonal and avian influenza viruses, with some cross-reactivity to N3 and N6 (group 2), and N1, N5, and N8 (group 1), as well as weak binding to influenza B NA. The 1E01 antibody has an intermediate binding profile, covering group 2 NAs (N2, N3, N6, N7, and N9), group 1 NAs (N1, N5, and N8), with strong binding to influenza B NA from the B/Victoria/2/87 lineage and weak binding to the NA of the B/Yamagata/16/88 lineage . These differences in binding profiles correlate with the extent of somatic hypermutation in each antibody, suggesting that affinity maturation through multiple influenza exposures likely contributed to the exceptional breadth of 1G01.

How does 1G01 inhibit neuraminidase activity?

The 1G01 antibody inhibits neuraminidase activity by directly binding to the active site of the enzyme. This mechanism was confirmed through multiple experimental approaches. In enzyme-linked lectin assays (ELLA) that measure neuraminidase inhibition (NI), 1G01 potently inhibited the activity of all influenza A group 1 and group 2 NAs, as well as B/Victoria/2/87 lineage NA. Additionally, its inhibitory activity was maintained in NA-Star assays, which use small molecule substrates and typically only detect inhibition by antibodies that directly target the active site .

Crucially, experiments using the antigen-binding fragment (Fab) of 1G01 instead of the full antibody in ELLA assays demonstrated that the 1G01 Fab still displayed potent inhibition (IC50 of 7.62 nM compared to 1.35 nM for the full antibody). This finding confirms that 1G01 inhibits NA activity by directly targeting the active site rather than through steric hindrance . The direct binding to the conserved active site explains the exceptional breadth of 1G01's inhibitory activity across diverse influenza neuraminidase subtypes and supports its potential as a therapeutic agent against a wide range of influenza viruses, including those resistant to oseltamivir.

What is the structural basis for 1G01's broad protection against influenza viruses?

The structural basis for 1G01's exceptionally broad protection was elucidated through crystal structure determination of the antibody in complex with the N1 NA of the 2009 pandemic H1N1 isolate A/California/04/2009 (CA04 N1) at 3.27 Å resolution. The structure revealed that 1G01 binds directly to the NA active site, with its 21-residue complementarity determining region (CDR) H3 playing a dominant role in the interaction. This long CDR H3 loop interacted with 19 CA04 N1 NA residues, including 13 NA-conserved active site or second-shell residues .

Unlike the other antibodies in its clonal family, 1G01 bound to the NA using only CDRs L1, L2, and H3, as well as one residue, Y67, from the framework region (FR) L3. The total buried surface area on the NA by 1G01 was 800 Ų, of which 77% arose from the heavy chain and 77% from the extended CDR H3 loop. This focused binding footprint, predominantly through the CDR H3, enables 1G01 to recognize the highly conserved active site across different NA subtypes . The interaction with conserved active site residues explains why 1G01 has the broadest reactivity among the three antibodies, despite having the smallest footprint. This structural insight highlights how 1G01's binding mode differs from previously characterized mouse NA antibodies, which typically bind to epitopes distant from the active site or on the rim of the active site.

How effective is 1G01 in in vivo protection studies against diverse influenza strains?

The 1G01 antibody demonstrated exceptional protective efficacy in mouse challenge models against a comprehensive panel of influenza viruses. When administered at 5 mg/kg two hours prior to infection, 1G01 provided full protection from lethality against all challenge viruses tested, including those expressing human N2, avian N2, swine N3, avian N6, N7, N9 NAs (all group 2), human N1, avian N1, N4, N5, and N8 NAs (all group 1), and an influenza B NA from the B/Victoria/2/87 lineage .

Remarkably, except for the N4 challenge where some transient weight loss was observed, 1G01 provided complete protection against weight loss across all virus challenges. When tested in a dose de-escalation study with an H3N2 challenge, 1G01 was fully protective for BALB/c mice at doses as low as 0.3 mg/kg and protected 80% of DBA/2J mice at 1 mg/kg . Furthermore, virus replication studies in the lungs of challenged animals showed no detectable replicating virus on days 3 and 6 post-infection using a plaque assay, indicating that 1G01's strong in vitro inhibiting and neutralizing activity translates to sterilizing immunity in vivo. Additional measurements using a limiting dilution method in embryonated eggs found only residual titers on day 3 post-infection and no virus in any treated mouse on day 6 post-infection . These comprehensive in vivo protection studies highlight 1G01's potential as a universal therapeutic agent against diverse influenza strains.

What are the mechanisms of protection mediated by 1G01 beyond neuraminidase inhibition?

While direct inhibition of neuraminidase activity is a primary mechanism of 1G01's antiviral action, the antibody also mediates additional protective effects through Fc-Fc receptor (FcR) interactions. The 1G01 antibody demonstrated activity in antibody-dependent cellular cytotoxicity (ADCC) bioreporter assays against a panel of different neuraminidases, even in cases where it exhibited relatively weak binding . This suggests that 1G01 can engage effector cells to target and eliminate infected cells expressing neuraminidase on their surface.

The multifaceted protective mechanisms of 1G01, combining direct enzymatic inhibition with Fc-mediated effector functions, likely contribute to its robust in vivo efficacy. This was evident in certain challenge models where protection was observed despite the absence of strong neuraminidase inhibition activity in vitro. For example, while 1G04 lacked strong NI activity against H4N6 and B/Malaysia.2506/2004, it still provided protection from challenge, suggesting that binding-mediated effector functions can, in combination with residual NI, provide protection from infection . The ability of 1G01 to harness both direct inhibition and immune effector mechanisms makes it a particularly promising candidate for therapeutic development, as it could potentially overcome resistance mechanisms that might emerge against single-mechanism antivirals.

How can researchers evaluate the neuraminidase inhibition activity of 1G01?

For methodological assessment, researchers should determine the 50% inhibitory concentration (IC50) values in both assays. For 1G01, an IC50 of 1.35 nM was observed in the NA-Star assay. To further confirm direct active site binding, researchers can generate and test the Fab fragment of 1G01 in the ELLA. The 1G01 Fab maintained potent inhibition with an IC50 of 7.62 nM, confirming direct active site targeting rather than steric hindrance . Additionally, researchers should test 1G01 against oseltamivir-resistant viruses to evaluate its potential against drug-resistant strains. In previous studies, 1G01 inhibited oseltamivir-resistant H3N2 viruses with similar potency as susceptible control viruses, indicating its potential value against drug-resistant influenza strains .

What protocol should be followed for in vivo protection studies with 1G01?

For in vivo protection studies with 1G01, researchers should follow a comprehensive protocol that evaluates protection against a diverse panel of influenza viruses representing different neuraminidase subtypes. Based on previous studies, the following methodological approach is recommended: First, administer 1G01 antibody at 5 mg/kg to mice two hours prior to infection with lethal doses of various influenza viruses. Monitor morbidity (weight loss) and mortality for 14 days post-infection .

For more detailed analysis, researchers should include dose de-escalation studies (testing doses as low as 0.3 mg/kg) using multiple mouse strains (e.g., BALB/c and DBA/2J) to establish minimum protective doses across genetic backgrounds. To assess viral clearance, investigators should collect lung samples on days 3 and 6 post-infection and measure virus replication using both plaque assays and limiting dilution methods in embryonated eggs . For therapeutic potential evaluation, researchers should also perform delayed treatment studies, administering 1G01 at 48- and 72-hours post-infection to determine its efficacy in established infections.

The comprehensive assessment should include viruses expressing neuraminidases from all major groups: group 1 (N1, N4, N5, N8), group 2 (N2, N3, N6, N7, N9), and influenza B. This methodological approach will provide a robust evaluation of 1G01's protective capacity and therapeutic potential against diverse influenza strains .

How can researchers analyze the structural interactions between 1G01 and neuraminidase?

To analyze the structural interactions between 1G01 and neuraminidase, researchers should employ X-ray crystallography to determine the complex structure. Based on previous successful approaches, the methodology involves crystallizing the 1G01 Fab in complex with recombinant neuraminidase proteins from representative virus strains. For comprehensive analysis, researchers should examine complexes with neuraminidases from different groups, such as the N1 NA of the 2009 pandemic H1N1 isolate (representing group 1), similar to the previously determined 3.27 Å resolution structure .

The structural analysis should focus on identifying the key interacting residues from both the antibody and the neuraminidase. For 1G01, particular attention should be paid to the 21-residue CDR H3, which dominated the interaction with 19 CA04 N1 NA residues in previous studies. Researchers should identify which of these interactions involve conserved active site residues versus subtype-specific residues . Additionally, comparison with structures of the same antibody bound to different NA subtypes can provide insights into the structural basis for cross-reactivity. Surface area calculations should be performed to quantify the contributions of different antibody regions to binding, with previous studies showing that 77% of the 800 Ų buried surface area on the NA by 1G01 arose from the heavy chain, and 77% specifically from the extended CDR H3 loop . This methodological approach will reveal the structural determinants of 1G01's exceptional breadth and inform structure-based vaccine design.

How can 1G01 guide universal influenza vaccine development?

The 1G01 antibody provides a valuable template for guiding universal influenza vaccine development through several methodological approaches. First, researchers can use 1G01's epitope within the conserved neuraminidase active site as a target for structure-based immunogen design. By creating stabilized or scaffolded constructs that present the 1G01 epitope in its optimal conformation, vaccine designers may be able to induce similar broadly neutralizing antibodies in vaccine recipients .

Second, the isolation of 1G01 demonstrates that humans can generate heterosubtypic anti-NA antibodies with exceptional breadth, countering previous assumptions that NA immunity is not heterosubtypic. Sequential prime-boost regimens with recombinant NA vaccines including different subtypes could potentially induce 1G01-like antibodies. This approach differs from earlier vaccine studies where broad protection was observed within a subtype but heterosubtypic immunity was not detected .

The finding that 1G01, 1E01, and 1G04 represented 6.67% of generated mAbs from the infected donor suggests that such broadly reactive antibodies may be relatively common in individuals with appropriate exposure histories. The antibody's reactivity profile suggests it likely developed through initial engagement by an H3N2 infection and subsequently acquired affinity to N1 and influenza B virus NA antigens through exposures to H1N1 and influenza B viruses . This natural development pathway could be mimicked through carefully designed vaccination regimens to induce similar broad protection against diverse influenza strains.

What are the potential therapeutic applications of 1G01?

The 1G01 antibody shows exceptional promise as a therapeutic agent against influenza viruses, with several methodological advantages over existing antivirals. First, 1G01's extraordinary breadth of protection against all influenza A virus NA subtypes and influenza B virus NA makes it a potential universal treatment option for seasonal, pandemic, and zoonotic influenza virus infections . Unlike subtype-specific treatments, a single 1G01-based therapeutic could potentially address any emerging influenza threat.

Third, 1G01 demonstrated therapeutic potential in mouse models when administered after infection. When given 48 or 72 hours post-infection with a lethal dose of H3N2 virus, a 5 mg/kg dose of antibody provided complete protection from mortality, although transient weight loss was observed . This therapeutic window is clinically relevant and suggests potential utility in treating established infections. The dual mechanisms of action—direct neuraminidase inhibition and Fc-mediated effector functions—likely contribute to 1G01's therapeutic efficacy and may provide advantages over single-mechanism antivirals. These properties position 1G01 as a promising candidate for development as a broadly protective therapeutic against diverse influenza viruses.

What are the key methodological considerations for producing and purifying 1G01?

For researchers working with 1G01, several methodological considerations are important for successful production and purification. Based on the original isolation protocol, 1G01 was generated by cloning the corresponding immunoglobulin heavy and light variable (IGHV and IGLV) chain genes from single sorted plasmablasts from peripheral blood mononuclear cells. The antibody was then expressed using established recombinant antibody production systems .

Researchers should note that 1G01 utilizes IGHV3-20 and IGKV1-9 genes with extensive somatic hypermutations, particularly in the IGHV genes. The 1G01 heavy chain differs from the germline gene IGHV3-20*04 at 19 positions, which is more than its clonal relatives 1G04 and 1E01 (with 12 and 14 differences, respectively) . These mutations are critical for its broad binding activity, and any expression system should maintain the exact sequence to preserve function.

For characterization, antigen-binding fragments (Fabs) of 1G01 should be generated for structural studies and to distinguish direct binding from steric effects in inhibition assays. Previous work showed that the 1G01 Fab bound with low nanomolar affinities to neuraminidase proteins and retained strong inhibitory activity in functional assays . When designing experiments with 1G01, researchers should consider both the full antibody and Fab formats depending on the specific research question being addressed.